StreetInsider.com News Articles

Form EFFECT ROCKET PHARMACEUTICALS,

Wed, 11 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260311/26142194.html

Form EFFECT ROCKET PHARMACEUTICALS,

Wed, 11 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260311/26142194.html

Form 8-K ROCKET PHARMACEUTICALS, For: Mar 10

Tue, 10 Mar 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260310/26140740.html

Form 8-K ROCKET PHARMACEUTICALS, For: Mar 10

Tue, 10 Mar 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260310/26140740.html

Form 424B5 ROCKET PHARMACEUTICALS,

Tue, 10 Mar 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260310/26140693.html

Form 424B5 ROCKET PHARMACEUTICALS,

Tue, 10 Mar 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260310/26140693.html

Rocket Pharmaceuticals (RCKT) files $400M mixed shelf

Mon, 02 Mar 2026 16:22:51 -0400

Rocket Pharmaceuticals (NASDAQ: RCKT) has filed $400,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units

Rocket Pharmaceuticals (RCKT) files $400M mixed shelf

Mon, 02 Mar 2026 16:22:51 -0400

Rocket Pharmaceuticals (NASDAQ: RCKT) has filed $400,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units

Form S-3 ROCKET PHARMACEUTICALS,

Mon, 02 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260302/26092409.html

Form S-3 ROCKET PHARMACEUTICALS,

Mon, 02 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260302/26092409.html

Rocket Pharmaceuticals (RCKT) PT Raised to $3 at Goldman Sachs

Mon, 02 Mar 2026 06:30:27 -0400

Goldman Sachs analyst Richard Law raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $3.00 (from $2.00) while maintaining a Sell rating.

Rocket Pharmaceuticals (RCKT) PT Raised to $10 at Cantor Fitzgerald

Fri, 27 Feb 2026 08:40:24 -0400

Cantor Fitzgerald analyst Josh Schimmer raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $10.00 (from $8.00) while maintaining a Overweight rating.

Rocket Pharmaceuticals (RCKT) Tops Q4 EPS by 5c

Thu, 26 Feb 2026 17:16:08 -0400

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.38), $0.05 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.

Form 8-K ROCKET PHARMACEUTICALS, For: Feb 26

Thu, 26 Feb 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260226/26071278.html

Form 8-K ROCKET PHARMACEUTICALS, For: Feb 26

Thu, 26 Feb 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260226/26071278.html

Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31

Thu, 26 Feb 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260226/26070577.html

Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31

Thu, 26 Feb 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260226/26070577.html

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Thu, 26 Feb 2026 16:00:00 -0400

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date

Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026

Cash, cash equivalents and investments of approximately $188.9M; expected operational runway into the second quarter of 2027